



1633

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Harvey D. PREISLER  
 Title: BINDING-SPECIFIC PEPTIDES,  
 BINDING-SPECIFIC CARRIER  
 MOLECULES, AND USES THEREOF  
 Appl. No.: 10/062,587  
 Filing Date: 1/31/02  
 Art Unit: 1633

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.

\_\_\_\_\_  
Robert N. Young  
(Printed Name)

\_\_\_\_\_  
\_\_\_\_\_  
(Signature)

\_\_\_\_\_  
June 5, 2002  
(Date of Deposit)

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56**

Commissioner for Patents  
 Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

RECEIVED  
JUN 14 2002  
TECH CENTER 1600/2002



COPY OF PAPERS  
ORIGINALLY FILED

Atty. Dkt. No. 047940-0135

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP § 609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 06-1447. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1447.

Respectfully submitted,

By

  
Robert N. Young  
Attorney for Applicant  
Registration No. 48,412

Date June 5, 2002

FOLEY & LARDNER  
Customer Number: 23524



23524

PATENT TRADEMARK OFFICE

Telephone: (608) 258-4991  
Facsimile: (608) 258-4258

O I P E S C I T A  
JUN 11 2002  
U. S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

COPY OF PAPERS  
ORIGINALLY FILED

Page 1 of 2

Form PTO-1449 (MODIFIED)	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 047940-0135	SERIAL NO. 10/062,587
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)		APPLICANT Harvey D. PREISLER		
		FILING DATE 01/31/2002	GROUP ART UNIT 1633	

U. S. PATENT DOCUMENTS


EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
KAC		5,512,435	4/30/96	Renschler et al.			RECEIVED
							JUN 14 2002

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	✓	A. Cabibbo et al., "Monovalent phage display of human interleukin (hIL)-6: selection of superbinder variants from a complex molecular repertoire in the hIL-6 D-helix," <u>Gene</u> 167, pp. 41-47, 1995; published by Elsevier Science B.V.
	✓	M. A. Barry et al., "Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries," <u>Nature Medicine</u> 2(3), pp. 299-305, March 1996.
	✓	R. Pasquallini and E. Ruoslahti, "Organ targeting <i>in vivo</i> using phage display peptide libraries," <u>Nature</u> 380, pp. 364-366, 1996.
	✓	J. W. Smith and E. Ruoslahti, "Harvesting Molecular Diversity - Biology's New Commodity," <u>Biotech Gen Eng Rev</u> 14, pp. 51-65, April 1997.
	✓	M. Szardenings et al., "Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1," <u>J Biol Chem</u> 272(44), pp. 27943-27948, 1997; published by The American Society for Biochemistry and Molecular Biology, Inc.
	✓	W. Arap et al., "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model," <u>Science</u> 279, pp. 377-380, January 1998.
↓	✓	W. Arap et al., "Chemotherapy targeted to tumor vasculature," <u>Curr Opin Oncol</u> 10, pp. 560-565, 1998.



COPY OF PAPERS  
ORIGINALLY FILED

Page 2 of 2

KAC		Samoylova and B. F. Smith, "Elucidation of muscle-binding peptides by phage display screening," <u>Muscle and Nerve</u> , pp. 460-466, April 1999.
	✓	J. D. Norris <i>et al.</i> , "Peptide antagonists of the human estrogen receptor," <u>Science</u> 285, pp. 744-746, July 1999.
	✓	V. V. Ivanenkov <i>et al.</i> , "Targeted delivery of multivalent phage display vectors into mammalian cells," <u>Biochimica et Biophysica Acta</u> 1448, pp. 463-472, 1999; published by Elsevier Science B.V.
	✓	E. Koivunen <i>et al.</i> , "Identification of receptor ligands with phage display peptide libraries," <u>J Nucl Med</u> 40, pp. 883-888, 1999.
	✓	L. Mazzucchelli <i>et al.</i> , "Cell-specific peptide binding by human neutrophils," <u>Blood</u> 93, pp. 1738-1748, 1999.
	✓	D. J. Rodi and L. Makowski, "Phage-display technology - finding a needle in a vast molecular haystack," <u>Curr Opin Biotechnol</u> 10(1), pp. 87-93, 1999; published by Elsevier Science B.V.
	✓	K. C. Brown, "New approaches for cell-specific targeting: Identification of cell-selective peptides from combinatorial libraries," <u>Curr Opin Chem Biol</u> 4, pp. 16-21, 2000; published by Elsevier Science B.V.
↓	✓	F. D. Hong and G. L. Clayman, "Isolation of a peptide for targeted drug delivery into human head and neck solid tumors," <u>Cancer Res</u> 60, pp. 6551-6556, December 2000.
EXAMINER		DATE CONSIDERED
/Karen A. Canella, Ph.D./		12/26/2006
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.		